Who
Ronald Todd Plott
Director
Company insider
Files Form 4 as: Director, Phio Pharmaceuticals; Director, BioPharmX.
In numbers
- Trades disclosed
- 13
- Buys
- 3
- Sells
- 0
- Bought
- $55K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 1 Feb 2019
- Last trade
- 29 Sep 2026
- Last filed
- 30 Sep 2026
Companies traded
Activity over time
1 Aug – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 29 Sep 2026filed 30 Sep 2026 | PHIO Phio PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $5,2005,000 at $1.04 | filing |
| 29 Sep 2026filed 30 Sep 2026 | PHIO Phio PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $5,2005,000 at $1.04 | filing |
| 28 Sep 2026filed 30 Sep 2026 | PHIO Phio PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $5,1505,000 at $1.03 | filing |
| 28 Sep 2026filed 30 Sep 2026 | PHIO Phio PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $5,1505,000 at $1.03 | filing |
| 28 Sep 2026filed 29 Sep 2026 | PHIO Phio PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —17,000 at $0.00 | filing |
| 28 Sep 2026filed 29 Sep 2026 | PHIO Phio PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —17,000 at $0.00 | filing |
| 19 Aug 2026filed 20 Aug 2026 | PHIO Phio PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $17K15,000 at $1.14 | filing |
| 19 Aug 2026filed 20 Aug 2026 | PHIO Phio PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $17K15,000 at $1.14 | filing |
| 12 Jun 2019filed 14 Jun 2019 | BioPharmXoption or derivative | SEC FORM 4 Code A | $27K32,700 at $0.84 | filing |
| 1 Feb 2019filed 21 Feb 2019 | BioPharmXoption or derivative | SEC FORM 4 Code A | $15K133,000 at $0.11 | filing |
| 1 Feb 2019filed 21 Feb 2019 | BioPharmXoption or derivative | SEC FORM 4 Code A | $22K200,000 at $0.11 | filing |
| 1 Feb 2019filed 21 Feb 2019 | BioPharmXoption or derivative | SEC FORM 4 Code A | $6,80034,000 at $0.20 | filing |
| 1 Feb 2019filed 21 Feb 2019 | BioPharmXoption or derivative | SEC FORM 4 Code A | $10K51,000 at $0.20 | filing |
News
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow SeriesPHIO · standard-freeholder.com · 19 Oct 2026Phio Pharmaceuticals Announces Successful Completion of First Commercial-Scale cGMP Batch of PH-762 Drug SubstancePHIO · intelligencer.ca · 13 Oct 2026
0 headlines in the last 90 days name Ronald Todd Plott; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.